Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

• Status: Not yet recruiting
• Trial end date: 2021-08-28
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this trial is to analyse the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke by Metabonomics, proteomics and clinical parameters.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Dongzhimen Hospital, Beijing
• Collaborators: Affiliated Hospital of Chengde Medical University; Nanjing Brian Hospital; Nantong University

Criteria

Inclusion Criteria:

• Diagnosis of Acute ischemic stroke；

• Symptom onset within 24 hours；

• 35 ≤ Age ≤ 80 years；

• 4 ≤ NIHSS ≤ 25；

• Patient or legally authorized representative has signed informed consent.

Exclusion Criteria:

• Expected length of hospital stay is less than 10 days;

• Planned or already receiving intravenous thrombolysis or endovascular treatment;

• Use of drugs with unknown composition within 1 week before enrollment;

• Patients with acute infectious diseases (e.g. acute pneumonia) or taking related drugs within 1 month before treatment in the group;

• Suspected secondary stroke caused by tumor, brain trauma, or hematological diseases;

• Already dependent in activities of daily living before the present acute stroke (defined as modified Rankin Scale score ≥ 2) ;

• Other conditions that cause cardiogenic embolism (e.g., atrial fibrillation, rheumatic heart disease, valvular heart disease);

• Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis, rheumatoid arthritis);

• Significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) value that is twice the upper limit of normal);

• Life expectancy of 3 months or less due to other life-threatening illness (e.g.,advanced cancer)

• Other conditions that render outcomes or follow-up unlikely to be assessed;

• Known to be pregnant or breastfeeding;

• Currently receiving an investigational drug.